Buy, Sell or Hold: Stryker Corp. (SYK-N) — Stock Predictions at Stockchase

skip to content

NYSE:SYK

254.68

2.34 (0.91%) 1d

Showing 1 to 15 of 113 entries

«
‹
1
2
3
4
5
›
»

Next Page

TOP PICK

73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’ price target is $284.10)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Oct 02/20, Up 34%) This was recommend before vaccines. This company benefits from elective surgery. These surgeries were not happening then. Expects them to report record earnings in 2021. Better days lie a head. Benefits from the aging population. Has intimate relationships with doctors. It is also a platform that is good at acquiring businesses.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Sep 14/20, Up 32%) Medical devices are an important place to be. Good acquisition right before the pandemic. Demographic play. Pandemic backlog should ease and improve revenues. Good opportunity globally for next few years.

biotechnology / pharmaceutical

TOP PICK

Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.

biotechnology / pharmaceutical

BUY

With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.

biotechnology / pharmaceutical

TOP PICK

Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)

biotechnology / pharmaceutical

BUY

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

biotechnology / pharmaceutical

TOP PICK

They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)

biotechnology / pharmaceutical

TOP PICK

It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.

biotechnology / pharmaceutical

TOP PICK

Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.

biotechnology / pharmaceutical

TOP PICK

The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)

biotechnology / pharmaceutical

Showing 1 to 15 of 113 entries

«
‹
1
2
3
4
5
›
»

Next Page

Stryker Corp.(SYK-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 7 stock analysts published opinions about SYK-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

7 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2022-01-21, Stryker Corp. (SYK-N) stock closed at a price of $254.68.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.